Respiratory Infectious Disease Diagnostics mainly focuses on breathing issues and X-ray or CT scan to check the lower respiratory tract. Sometimes, fluid and inflammation in the lungs is also checked.
The global market for Respiratory Infectious Disease Diagnostics was estimated to be worth US$ 64120 million in 2023 and is forecast to a readjusted size of US$ 75130 million by 2030 with a CAGR of 2.2% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Respiratory Infectious Disease Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Respiratory Infectious Disease Diagnostics by region & country, by Type, and by Application.
The Respiratory Infectious Disease Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Infectious Disease Diagnostics.
麻豆原创 Segmentation
By Company
Abbott Laboratories
Thermo Fisher Scientific.
Koninklijke Philips
Cardinal Health
COSMED
Smiths Group
NIHON KOHDEN CORPORATION
Becton
Dickinson
F.Hoffmann
bioM茅rieux SA
Bio-Rad Laboratories, Inc.
Quidel Corporation
Siemens Healthcare GmbH
Danaher
Qiagen
GENERAL ELECTRIC COMPANY
Medtronic
Novartis AG
Johnson & Johnson Services Inc
GlaxoSmithKline plc
Dr盲gerwerk AG & Co. KGaA
GC Diagnostics Corporation
Bayer AG
Masimo
Carestream Health
Segment by Type:
Mechanical Tests
Imaging Tests
In Vitro Diagnostics (IVD) Tests
Segment by Application
Hospitals
Clinical Laboratories
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Respiratory Infectious Disease Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Respiratory Infectious Disease Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Respiratory Infectious Disease Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Respiratory Infectious Disease Diagnostics Product Introduction
1.2 Global Respiratory Infectious Disease Diagnostics 麻豆原创 Size Forecast
1.3 Respiratory Infectious Disease Diagnostics 麻豆原创 Trends & Drivers
1.3.1 Respiratory Infectious Disease Diagnostics Industry Trends
1.3.2 Respiratory Infectious Disease Diagnostics 麻豆原创 Drivers & Opportunity
1.3.3 Respiratory Infectious Disease Diagnostics 麻豆原创 Challenges
1.3.4 Respiratory Infectious Disease Diagnostics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Respiratory Infectious Disease Diagnostics Players Revenue Ranking (2023)
2.2 Global Respiratory Infectious Disease Diagnostics Revenue by Company (2019-2024)
2.3 Key Companies Respiratory Infectious Disease Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Respiratory Infectious Disease Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Respiratory Infectious Disease Diagnostics
2.6 Respiratory Infectious Disease Diagnostics 麻豆原创 Competitive Analysis
2.6.1 Respiratory Infectious Disease Diagnostics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Respiratory Infectious Disease Diagnostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Infectious Disease Diagnostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Mechanical Tests
3.1.2 Imaging Tests
3.1.3 In Vitro Diagnostics (IVD) Tests
3.2 Global Respiratory Infectious Disease Diagnostics Sales Value by Type
3.2.1 Global Respiratory Infectious Disease Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Respiratory Infectious Disease Diagnostics Sales Value, by Type (2019-2030)
3.2.3 Global Respiratory Infectious Disease Diagnostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinical Laboratories
4.1.3 Others
4.2 Global Respiratory Infectious Disease Diagnostics Sales Value by Application
4.2.1 Global Respiratory Infectious Disease Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Respiratory Infectious Disease Diagnostics Sales Value, by Application (2019-2030)
4.2.3 Global Respiratory Infectious Disease Diagnostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Respiratory Infectious Disease Diagnostics Sales Value by Region
5.1.1 Global Respiratory Infectious Disease Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Respiratory Infectious Disease Diagnostics Sales Value by Region (2019-2024)
5.1.3 Global Respiratory Infectious Disease Diagnostics Sales Value by Region (2025-2030)
5.1.4 Global Respiratory Infectious Disease Diagnostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
5.2.2 North America Respiratory Infectious Disease Diagnostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
5.3.2 Europe Respiratory Infectious Disease Diagnostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
5.4.2 Asia Pacific Respiratory Infectious Disease Diagnostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
5.5.2 South America Respiratory Infectious Disease Diagnostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
5.6.2 Middle East & Africa Respiratory Infectious Disease Diagnostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Respiratory Infectious Disease Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Respiratory Infectious Disease Diagnostics Sales Value
6.3 United States
6.3.1 United States Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
6.3.2 United States Respiratory Infectious Disease Diagnostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Respiratory Infectious Disease Diagnostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
6.4.2 Europe Respiratory Infectious Disease Diagnostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Respiratory Infectious Disease Diagnostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
6.5.2 China Respiratory Infectious Disease Diagnostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Respiratory Infectious Disease Diagnostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
6.6.2 Japan Respiratory Infectious Disease Diagnostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Respiratory Infectious Disease Diagnostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
6.7.2 South Korea Respiratory Infectious Disease Diagnostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Respiratory Infectious Disease Diagnostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
6.8.2 Southeast Asia Respiratory Infectious Disease Diagnostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Respiratory Infectious Disease Diagnostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Respiratory Infectious Disease Diagnostics Sales Value, 2019-2030
6.9.2 India Respiratory Infectious Disease Diagnostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Respiratory Infectious Disease Diagnostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Profile
7.1.2 Abbott Laboratories Main Business
7.1.3 Abbott Laboratories Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.1.4 Abbott Laboratories Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.1.5 Abbott Laboratories Recent Developments
7.2 Thermo Fisher Scientific.
7.2.1 Thermo Fisher Scientific. Profile
7.2.2 Thermo Fisher Scientific. Main Business
7.2.3 Thermo Fisher Scientific. Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.2.4 Thermo Fisher Scientific. Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.2.5 Thermo Fisher Scientific. Recent Developments
7.3 Koninklijke Philips
7.3.1 Koninklijke Philips Profile
7.3.2 Koninklijke Philips Main Business
7.3.3 Koninklijke Philips Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.3.4 Koninklijke Philips Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.3.5 Cardinal Health Recent Developments
7.4 Cardinal Health
7.4.1 Cardinal Health Profile
7.4.2 Cardinal Health Main Business
7.4.3 Cardinal Health Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.4.4 Cardinal Health Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.4.5 Cardinal Health Recent Developments
7.5 COSMED
7.5.1 COSMED Profile
7.5.2 COSMED Main Business
7.5.3 COSMED Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.5.4 COSMED Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.5.5 COSMED Recent Developments
7.6 Smiths Group
7.6.1 Smiths Group Profile
7.6.2 Smiths Group Main Business
7.6.3 Smiths Group Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.6.4 Smiths Group Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.6.5 Smiths Group Recent Developments
7.7 NIHON KOHDEN CORPORATION
7.7.1 NIHON KOHDEN CORPORATION Profile
7.7.2 NIHON KOHDEN CORPORATION Main Business
7.7.3 NIHON KOHDEN CORPORATION Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.7.4 NIHON KOHDEN CORPORATION Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.7.5 NIHON KOHDEN CORPORATION Recent Developments
7.8 Becton
7.8.1 Becton Profile
7.8.2 Becton Main Business
7.8.3 Becton Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.8.4 Becton Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.8.5 Becton Recent Developments
7.9 Dickinson
7.9.1 Dickinson Profile
7.9.2 Dickinson Main Business
7.9.3 Dickinson Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.9.4 Dickinson Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.9.5 Dickinson Recent Developments
7.10 F.Hoffmann
7.10.1 F.Hoffmann Profile
7.10.2 F.Hoffmann Main Business
7.10.3 F.Hoffmann Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.10.4 F.Hoffmann Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.10.5 F.Hoffmann Recent Developments
7.11 bioM茅rieux SA
7.11.1 bioM茅rieux SA Profile
7.11.2 bioM茅rieux SA Main Business
7.11.3 bioM茅rieux SA Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.11.4 bioM茅rieux SA Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.11.5 bioM茅rieux SA Recent Developments
7.12 Bio-Rad Laboratories, Inc.
7.12.1 Bio-Rad Laboratories, Inc. Profile
7.12.2 Bio-Rad Laboratories, Inc. Main Business
7.12.3 Bio-Rad Laboratories, Inc. Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.12.4 Bio-Rad Laboratories, Inc. Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.12.5 Bio-Rad Laboratories, Inc. Recent Developments
7.13 Quidel Corporation
7.13.1 Quidel Corporation Profile
7.13.2 Quidel Corporation Main Business
7.13.3 Quidel Corporation Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.13.4 Quidel Corporation Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.13.5 Quidel Corporation Recent Developments
7.14 Siemens Healthcare GmbH
7.14.1 Siemens Healthcare GmbH Profile
7.14.2 Siemens Healthcare GmbH Main Business
7.14.3 Siemens Healthcare GmbH Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.14.4 Siemens Healthcare GmbH Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.14.5 Siemens Healthcare GmbH Recent Developments
7.15 Danaher
7.15.1 Danaher Profile
7.15.2 Danaher Main Business
7.15.3 Danaher Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.15.4 Danaher Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.15.5 Danaher Recent Developments
7.16 Qiagen
7.16.1 Qiagen Profile
7.16.2 Qiagen Main Business
7.16.3 Qiagen Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.16.4 Qiagen Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.16.5 Qiagen Recent Developments
7.17 GENERAL ELECTRIC COMPANY
7.17.1 GENERAL ELECTRIC COMPANY Profile
7.17.2 GENERAL ELECTRIC COMPANY Main Business
7.17.3 GENERAL ELECTRIC COMPANY Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.17.4 GENERAL ELECTRIC COMPANY Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.17.5 GENERAL ELECTRIC COMPANY Recent Developments
7.18 Medtronic
7.18.1 Medtronic Profile
7.18.2 Medtronic Main Business
7.18.3 Medtronic Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.18.4 Medtronic Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.18.5 Medtronic Recent Developments
7.19 Novartis AG
7.19.1 Novartis AG Profile
7.19.2 Novartis AG Main Business
7.19.3 Novartis AG Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.19.4 Novartis AG Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.19.5 Novartis AG Recent Developments
7.20 Johnson & Johnson Services Inc
7.20.1 Johnson & Johnson Services Inc Profile
7.20.2 Johnson & Johnson Services Inc Main Business
7.20.3 Johnson & Johnson Services Inc Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.20.4 Johnson & Johnson Services Inc Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.20.5 Johnson & Johnson Services Inc Recent Developments
7.21 GlaxoSmithKline plc
7.21.1 GlaxoSmithKline plc Profile
7.21.2 GlaxoSmithKline plc Main Business
7.21.3 GlaxoSmithKline plc Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.21.4 GlaxoSmithKline plc Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.21.5 GlaxoSmithKline plc Recent Developments
7.22 Dr盲gerwerk AG & Co. KGaA
7.22.1 Dr盲gerwerk AG & Co. KGaA Profile
7.22.2 Dr盲gerwerk AG & Co. KGaA Main Business
7.22.3 Dr盲gerwerk AG & Co. KGaA Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.22.4 Dr盲gerwerk AG & Co. KGaA Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.22.5 Dr盲gerwerk AG & Co. KGaA Recent Developments
7.23 GC Diagnostics Corporation
7.23.1 GC Diagnostics Corporation Profile
7.23.2 GC Diagnostics Corporation Main Business
7.23.3 GC Diagnostics Corporation Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.23.4 GC Diagnostics Corporation Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.23.5 GC Diagnostics Corporation Recent Developments
7.24 Bayer AG
7.24.1 Bayer AG Profile
7.24.2 Bayer AG Main Business
7.24.3 Bayer AG Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.24.4 Bayer AG Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.24.5 Bayer AG Recent Developments
7.25 Masimo
7.25.1 Masimo Profile
7.25.2 Masimo Main Business
7.25.3 Masimo Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.25.4 Masimo Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.25.5 Masimo Recent Developments
7.26 Carestream Health
7.26.1 Carestream Health Profile
7.26.2 Carestream Health Main Business
7.26.3 Carestream Health Respiratory Infectious Disease Diagnostics Products, Services and Solutions
7.26.4 Carestream Health Respiratory Infectious Disease Diagnostics Revenue (US$ Million) & (2019-2024)
7.26.5 Carestream Health Recent Developments
8 Industry Chain Analysis
8.1 Respiratory Infectious Disease Diagnostics Industrial Chain
8.2 Respiratory Infectious Disease Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Respiratory Infectious Disease Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Respiratory Infectious Disease Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Abbott Laboratories
Thermo Fisher Scientific.
Koninklijke Philips
Cardinal Health
COSMED
Smiths Group
NIHON KOHDEN CORPORATION
Becton
Dickinson
F.Hoffmann
bioM茅rieux SA
Bio-Rad Laboratories, Inc.
Quidel Corporation
Siemens Healthcare GmbH
Danaher
Qiagen
GENERAL ELECTRIC COMPANY
Medtronic
Novartis AG
Johnson & Johnson Services Inc
GlaxoSmithKline plc
Dr盲gerwerk AG & Co. KGaA
GC Diagnostics Corporation
Bayer AG
Masimo
Carestream Health
听
听
*If Applicable.
